SCHEMBL20134792

SCHEMBL20134792

Cc1ccc(-n2nnc(C3CCN(C(=O)c4ccc([C@@]5(C)NC(=O)NC5=O)cc4)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
MAPK7 Q13164 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
ADAMTS7 Q9UKP4 1/20 0.37
CRBN Q96SW2 2/20 0.37
TP53 P04637 1/20 0.36
HSD11B1 P28845 1/20 0.36
MGLL Q99685 1/20 0.36
PKM P14618 1/20 0.35
HPGD P15428 2/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134794 1.00 MEN1 (0.39) MEN1KMT2AUBE2MDCUN1D1MAPK7
SCHEMBL20135570 0.88 ADAMTS5 (0.38) MEN1KMT2AUBE2MDCUN1D1MMP2
SCHEMBL20135569 0.88 ADAMTS5 (0.38) MEN1KMT2AUBE2MDCUN1D1MMP2
SCHEMBL20135362 0.82 UBE2M (0.39) MEN1KMT2AUBE2MDCUN1D1MAPK7
SCHEMBL20135363 0.82 UBE2M (0.39) MEN1KMT2AUBE2MDCUN1D1MAPK7
SCHEMBL20134877 0.79 MEN1 (0.65) MEN1KMT2AHSD11B1MGLLLMNA
SCHEMBL20134876 0.79 MEN1 (0.65) MEN1KMT2AHSD11B1MGLLLMNA
SCHEMBL20134973 0.79 MGLL (0.39) MEN1KMT2AUBE2MDCUN1D1MAPK7
SCHEMBL20134970 0.79 MGLL (0.39) MEN1KMT2AUBE2MDCUN1D1MAPK7
SCHEMBL20134774 0.79 UBE2M (0.39) MEN1KMT2AUBE2MDCUN1D1MAPK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MEN1 3735/4885KMT2A 2568/4885UBE2M 2697/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MEN1 2913/4885KMT2A 2539/4885UBE2M 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.